KR20050075045A - Composition comprising mixture of the extract of grape seed and salicornia herbacea for lowering blood glucose and treating and preventing obesity - Google Patents
Composition comprising mixture of the extract of grape seed and salicornia herbacea for lowering blood glucose and treating and preventing obesity Download PDFInfo
- Publication number
- KR20050075045A KR20050075045A KR1020040002805A KR20040002805A KR20050075045A KR 20050075045 A KR20050075045 A KR 20050075045A KR 1020040002805 A KR1020040002805 A KR 1020040002805A KR 20040002805 A KR20040002805 A KR 20040002805A KR 20050075045 A KR20050075045 A KR 20050075045A
- Authority
- KR
- South Korea
- Prior art keywords
- grape seed
- extract
- mixture
- extract mixture
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 87
- 239000000284 extract Substances 0.000 title claims abstract description 77
- 229940087559 grape seed Drugs 0.000 title claims abstract description 33
- 210000004369 blood Anatomy 0.000 title claims abstract description 30
- 239000008280 blood Substances 0.000 title claims abstract description 30
- 208000008589 Obesity Diseases 0.000 title claims abstract description 20
- 235000020824 obesity Nutrition 0.000 title claims abstract description 20
- 241000047339 Salicornia brachystachya Species 0.000 title claims abstract description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title description 13
- 239000008103 glucose Substances 0.000 title description 12
- 241001474374 Blennius Species 0.000 claims abstract description 29
- 235000000346 sugar Nutrition 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 17
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 230000036541 health Effects 0.000 claims abstract description 8
- 235000013376 functional food Nutrition 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 229940087603 grape seed extract Drugs 0.000 claims description 13
- 235000002532 grape seed extract Nutrition 0.000 claims description 13
- 239000001717 vitis vinifera seed extract Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 239000002075 main ingredient Substances 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 17
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 14
- 241001465754 Metazoa Species 0.000 abstract description 8
- 241000699670 Mus sp. Species 0.000 abstract description 8
- 230000004584 weight gain Effects 0.000 abstract description 5
- 235000019786 weight gain Nutrition 0.000 abstract description 5
- 235000005911 diet Nutrition 0.000 abstract description 2
- 230000037213 diet Effects 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 38
- 102000004877 Insulin Human genes 0.000 description 19
- 108090001061 Insulin Proteins 0.000 description 19
- 229940125396 insulin Drugs 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 15
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 208000013016 Hypoglycemia Diseases 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 235000004347 Perilla Nutrition 0.000 description 4
- 244000124853 Perilla frutescens Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 241000219095 Vitis Species 0.000 description 4
- 235000009754 Vitis X bourquina Nutrition 0.000 description 4
- 235000012333 Vitis X labruscana Nutrition 0.000 description 4
- 235000014787 Vitis vinifera Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000013116 obese mouse model Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000000052 vinegar Substances 0.000 description 3
- 235000021419 vinegar Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 241000219094 Vitaceae Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000021021 grapes Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000871189 Chenopodiaceae Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000201895 Salicornia Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- -1 butanol or the like Chemical class 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229940038487 grape extract Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03B—APPARATUS OR ARRANGEMENTS FOR TAKING PHOTOGRAPHS OR FOR PROJECTING OR VIEWING THEM; APPARATUS OR ARRANGEMENTS EMPLOYING ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ACCESSORIES THEREFOR
- G03B17/00—Details of cameras or camera bodies; Accessories therefor
- G03B17/56—Accessories
- G03B17/566—Accessory clips, holders, shoes to attach accessories to camera
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16M—FRAMES, CASINGS OR BEDS OF ENGINES, MACHINES OR APPARATUS, NOT SPECIFIC TO ENGINES, MACHINES OR APPARATUS PROVIDED FOR ELSEWHERE; STANDS; SUPPORTS
- F16M11/00—Stands or trestles as supports for apparatus or articles placed thereon ; Stands for scientific apparatus such as gravitational force meters
- F16M11/02—Heads
- F16M11/04—Means for attachment of apparatus; Means allowing adjustment of the apparatus relatively to the stand
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03B—APPARATUS OR ARRANGEMENTS FOR TAKING PHOTOGRAPHS OR FOR PROJECTING OR VIEWING THEM; APPARATUS OR ARRANGEMENTS EMPLOYING ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ACCESSORIES THEREFOR
- G03B17/00—Details of cameras or camera bodies; Accessories therefor
- G03B17/56—Accessories
- G03B17/563—Camera grips, handles
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N23/00—Cameras or camera modules comprising electronic image sensors; Control thereof
- H04N23/50—Constructional details
Landscapes
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Multimedia (AREA)
- Signal Processing (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 혈당강하 효과가 있는 포도씨 및 함초(Salicornia herbacea)의 추출혼합물을 주성분으로 포함하는 조성물에 관한 것으로, 본 발명의 포도씨 및 함초의 추출혼합물은 당뇨병 모델 동물인 ob 마우스의 혈당을 낮추는 효과가 탁월할 뿐 아니라 체중 증가도 억제하여 당뇨병 및 다이어트에 효과가 있으므로, 상기 포도씨 및 함초의 추출혼합물을 주성분으로 포함하는 조성물은 혈당강하 및 비만의 치료 및 예방에 효과적인 의약품 및 건강기능식품을 제공한다.The present invention relates to a composition comprising an extract mixture of grape seed and Salicornia herbacea having a hypoglycemic effect as a main component, the extract mixture of the grape seed and seaweed of the present invention has an effect of lowering the blood sugar of ob mice, diabetic model animals Not only is it excellent, but also inhibits weight gain and is effective in diabetes and diet, the composition comprising the extract mixture of grape seed and seaweed as a main component provides a pharmaceutical and health functional food effective for the treatment and prevention of blood sugar lowering and obesity.
Description
본 발명은 포도씨 및 함초의 추출혼합물을 주성분으로 포함하는 혈당강하 및 비만의 치료 및 예방용 조성물을 제공한다.The present invention provides a composition for the treatment and prevention of hypoglycemia and obesity comprising the extract mixture of grape seed and perilla as a main component.
당뇨병(diabetes mellitus)은 그 이름에서 알 수 있듯이 소변에 당이 포함되어 배출이 되는 것을 의미하며 고혈당증(hyperglycemia)을 특징으로 하는 매우 흔한 질병이다. 우리나라 비만 성인의 대부분이 혈당치가 상당히 높은 당뇨병 환자로 매년 그 수가 급격하게 늘고 있으며, 더 큰 문제는 현재 10대 아동의 30 % 이상이 비만 환자라는데 있다. 혈 중의 당은 인슐린(insulin)에 의해 조절이 되는 것으로 알려져 있는데, 인슐린의 분비는 췌장(pancreas)의 베타(β)세포에 의해 유도된다. Diabetes mellitus, as its name suggests, means that sugar is contained in urine and is a very common disease characterized by hyperglycemia. Most of the obese adults in Korea are diabetic patients with high blood sugar, and the number is increasing rapidly every year. The bigger problem is that more than 30% of teenagers are obese patients. Sugar in the blood is known to be regulated by insulin (insulin), the secretion of insulin is induced by the beta (β) cells of the pancreas (pancreas).
따라서 인슐린을 분비하는 췌장의 베타세포의 상태 및 인슐린의 저항성에 따라 당뇨병은 2가지로 구분될 수 있다. 하나는 제1형(type Ⅰ)으로 인슐린의존성 당뇨병(insulin dependent diabetes mellitus)이라고 하며, 췌장의 베타세포가 바이러스의 감염이나 세포매개성 자가면역 질환에 의해 파괴되어 나타나는 것으로 인슐린을 생성하는 베타세포가 없기 때문에 혈당을 조절하지 못한다. 이러한 인슐린 의존성 당뇨병은 주로 젊은 계층에서 나타나며, 발병 빈도는 전체 당뇨병의 10-15 % 정도를 차지하는 것으로 알려져 있다. Therefore, diabetes may be classified into two types according to the state of beta-cells and insulin resistance of the pancreas that secrete insulin. One is type I (insulin dependent diabetes mellitus), and the beta cells of the pancreas are destroyed by viral infection or cell-mediated autoimmune disease. Because it does not control blood sugar. These insulin-dependent diabetes mellitus is mainly seen in younger people, the incidence is known to account for about 10-15% of all diabetes.
한편 이와는 반대로 제2형(type Ⅱ)은 인슐린을 분비하는 췌장의 베타세포가 정상상태로 있지만 체내의 인슐린 내성(insulin resistance)이나 인슐린 분비의 부족에 의해 나타나는 것으로 인슐린비의존성 당뇨병(non-insulin dependent diabetes mellitus)이라고 한다. 일반적으로 인슐린비의존성 당뇨병은 나이가 많은 성인이나 비만인 청소년들에게서 나타나며, 전 세계 당뇨병 환자의 85 %를 차지하고 있다. 인슐린비의존성 당뇨병은 유전적인 인자와 환경적인 인자에 의해 나타날 수 있는 매우 복잡한 질병이다. 특히 당뇨병의 가족력이 있는 경우나 일란성 쌍둥이의 경우 70 % 이상에서 당뇨병이 관찰되는 것으로 미루어 볼 때 유전적 요인이 매우 중요하게 작용하는 것을 알 수가 있다(O'Rahilly S, et al., Diabetologia, 31 pp792-797, 1988; Barnett AH, et al., Diabetologia, 20, pp87-93, 1981).On the other hand, type II (type II) is a pancreatic beta-cell that secretes insulin, but it is caused by insulin resistance in the body or lack of insulin secretion. diabetes mellitus). In general, insulin-independent diabetes occurs in older adults and obese adolescents, accounting for 85% of people with diabetes worldwide. Insulin-independent diabetes is a very complex disease that can be caused by genetic and environmental factors. Genetic factors play an important role, especially in the presence of a family history of diabetes or in over 70% of identical twins (O'Rahilly S, et al., Diabetologia , 31). pp 792-797, 1988; Barnett AH, et al., Diabetologia , 20 , pp87-93, 1981).
또한 비만의 경우 질병 발생을 촉진시키는 역할을 하는 것으로 알려져 있는데, 비만시에는 대체적으로 인슐린의 분비이상이 나타나게 된다. 그 이유는 음식물의 과다섭취에 의한 혈당의 증가가 췌장의 인슐린 분비를 촉진하여 과다한 인슐린이 혈 중으로 분비하게 된다. 이 때 과다로 분비된 인슐린에 의해 혈액은 고인슐린혈증(hyperinsulinemia)을 유발하고, 고인슐린혈증으로 인해서 간과 같은 표적장기는 과도한 반응을 하게 되며, 과도한 반응을 줄이기 위해 인슐린 수용체가 줄어들게 된다. 이러한 인슐린 수용체 저하는 결국 인슐린에 대한 반응을 줄이기 때문에 정상적으로 췌장에서 인슐린을 분비하더라도 결국 인슐린에 의한 효과는 급격하게 감소하게 되고, 이로 인해 당이 증가하였을 때 혈당을 억제하지 못해 혈 중 당의 농도가 급격히 상승하게 되는 것이다(Smith U., et al., Int. J. Obes. Relat. Metab. Disord., 26, pp897-904, 2002).In addition, obesity is known to play a role in facilitating the development of the disease, when obesity is usually the secretion of insulin appears. The reason is that an increase in blood sugar caused by excessive intake of food promotes insulin secretion of the pancreas and excess insulin is secreted into the blood. At this time, blood secreted by excessive insulin causes hyperinsulinemia, hyperinsulinemia causes target organs such as the liver to react excessively, and insulin receptors are reduced to reduce the excessive response. This decrease in insulin receptor eventually decreases the response to insulin, so even if the pancreas secretes insulin normally, the effect of insulin eventually decreases rapidly. As a result, the concentration of glucose in the blood is rapidly suppressed because glucose is not suppressed when glucose is increased. (Smith U., et al., Int. J. Obes. Relat. Metab. Disord. , 26 , pp897-904, 2002).
지금까지 당뇨병의 치료를 위한 연구는 지속적으로 수행되고 있는데, 당뇨의 억제를 위해서는 식이요법 및 운동, 인슐린의 직접 투여나 혈당강하 약물이 효과적인 것으로 알려져 있다. 혈당강하 약물로 알려진 것에는 설포닐유레아, 티아졸리딘디온, 비구아니드 등이 있는데, 이들이 효과적으로 혈당을 낮추기는 하지만, 부작용이 매우 큰 것으로 알려져 있다. 설포닐유레아의 경우 저혈당증이나 소화불량, 현기증, 졸림 등의 경미한 증상에서부터 신장 및 간 질환, 심혈관 사망률의 증가 등을 유발하는 것으로 알려져 그 사용에 매우 제약이 따른다. 한편 티아졸리딘디온은 인슐린이 있는 환경에서 인슐린에 의한 반응을 증진시켜 주는 것이므로, 인슐린이 체내에서 분비되는 경우에만 사용이 가능하며, 적혈구의 형태 이상 등을 유발하여, 현기증, 두통 등을 유발하고, 단지 인슐린의 존재시에 효과적이며 적혈구 이상 및 두통을 유발할 수 있다(Mayerson AB, et al., Am. Fam. Physician, 55 pp817-824, 1997; Vannasaeng S, et al., J. Med. Assoc. Thai., 78, pp578-585, 1995). 이러한 부작용 때문에 합성물질의 사용에는 매우 제약이 많이 따르므로, 합성물질보다는 천연물질의 사용이 부작용을 줄여 주는데 매우 중요한 역할을 할 것으로 생각된다.Until now, researches for the treatment of diabetes have been continuously conducted. For the prevention of diabetes, diet and exercise, direct administration of insulin or hypoglycemic drugs are known to be effective. Known hypoglycemic drugs include sulfonylureas, thiazolidinediones, biguanides, etc., although they effectively lower blood sugar, but are known to have very high side effects. Sulfonyl urea is known to cause mild symptoms such as hypoglycemia, indigestion, dizziness, and drowsiness, kidney and liver disease, and cardiovascular mortality, which is very limited in its use. On the other hand, thiazolidinedione enhances the response of insulin in the presence of insulin, so it can be used only when insulin is secreted in the body, causing abnormalities in erythrocytes, causing dizziness, headache, etc. , Effective only in the presence of insulin and can cause erythrocyte abnormalities and headaches (Mayerson AB, et al., Am. Fam. Physician , 55 pp 817-824, 1997; Vannasaeng S, et al., J. Med. Assoc Thai. , 78 , pp 578-585, 1995). Because of these side effects, the use of synthetic materials is very restrictive, it is thought that the use of natural materials rather than synthetic materials will play a very important role in reducing the side effects.
또한, 각종 질병을 촉진시키는 역할을 하며, 인슐린의 분비이상을 초래하는 비만을 조절할 시 당뇨병의 치료 및 예방에도 더욱 효과적일 것으로 사료된다. In addition, it plays a role of promoting various diseases, and it is thought that it is more effective in the treatment and prevention of diabetes when controlling obesity that causes abnormal secretion of insulin.
포도씨는 이시진(李時珍)의 본초강목(本草綱目)에서 포도는 힘줄과 뼈의 습비를 다스리고 기를 높여 힘을 세게 해주며, 의지를 굳게 해주고 건강하게 해주며, 또한 허기를 참을 수 있는 인내력을 주며 감기에 강하게 하는 등의 효과가 있으므로, 포도를 오래 먹으면 몸이 가벼워지고 늙지 않아 오래 살 수 있다고 하였다. Grape seed in the main sichuan of Lee Si-jin, the grapes control the strength and tenderness of the tendons and bones, strengthens the strength, strengthens the will, makes it healthy, and gives endurance to endure hunger and colds. It is said that it is effective in strengthening, so if you eat grapes for a long time, your body will become lighter and not old.
상기와 같이 포도씨의 추출물은 생리학적 효능이 우수하여 기능성 식품 또는 치료제 등으로 개발하려는 시도가 활발히 이루어지고 있는 바, 한국 공개특허 제 98-51189호에서 티로시나제 저해제로서의 포도씨 추출물, 한국 등록특허 제 00-18117호에서 포도씨 추출 천연 항충치제, 한국 공개특허 제 01-12238호에서 포도씨 추출물로 코팅된 쌀 등의 상기 포도씨 추출물을 함유하는 기능성 식품을 개시한 바 있으며, 한국공개특허 제 00-63265호에서 항산화 물질이 함유된 포도씨 기름과 그 제조방법, 한국공개특허 제 01-04553호에서 항산화 효과가 향상된 포도제품의 제조방법, 한국공개특허 제 99-28877호에서 프로시아니딘을 유효성분으로 하는 약효제 등 포도씨추출물의 주성분인 프로안토시아니딘(proanthocyanidin)의 항산화 효능에 대한 용도에 관하여 개시한 바 있다. As described above, the extract of grape seed has an excellent physiological effect, and has been actively attempted to be developed as a functional food or a therapeutic agent. In the Korean Patent Publication No. 98-51189, the grape seed extract as a tyrosinase inhibitor, Korean Patent No. 00-00 18117 discloses a natural food containing grape seed extract, such as rice seed coated with a grape seed extract, natural anti cavities, Korean Patent Publication No. 01-12238, and in Korea Patent Publication No. 00-63265 Grape seed oil containing antioxidants and a method of manufacturing the same, a method of producing grape products with improved antioxidant effect in Korean Patent Laid-Open Publication No. 01-04553, and a grape seed such as a medicinal agent using procyanidin as an active ingredient in Korean Patent Publication No. 99-28877 The use of the antioxidant component of proanthocyanidin, the main component of the extract, has been disclosed. .
함초(Salicornia herbacea)는 명주아과(chenopodiaceae)에 속하는 일년초로서, 신농초본경에는 맛이 짜다고 하여 함초(鹹草), 염초(鹽草) 또는 신령스러운 풀로 여겨 신초(神草)라고 적혀있으며, 해안이나 개펄, 염전 주위에 무리지어 자라서 '퉁퉁마디'라고도 불리우며, 1921년에 천연기념물로 지정되었다. 함초는 육지에 자라면서도 바닷물 속에 들어있는 갖가지 미네랄과 효소 성분이 농축되어 있으며, 특히 함초 100 g에 칼슘 671 ㎎, 마그네슘 661 ㎎, 칼륨 475 ㎎, 철 441 ㎎, 인 139 ㎎, 요오드 65.8 ㎎, 나트륨 6.5 %, 염분 15.7 % 등의 성분이 알려져 있고, 식물성 섬유질 5,200 ㎎ 및 숙변을 분해하는 효소군이 함유되어 있고, 이밖에 90여 가지의 미네랄이 골고루 들어있다. 약리작용으로는 신장염, 간염 및 고혈압, 저혈압, 빈혈증에 효과가 있고, 갑상선 기능 향상 등의 작용을 한다. Salicornia herbacea is an annual herb belonging to the chenopodiaceae, and it is written as sincho (herbaceous plant) because it is said to be salty, salty, or sacred grass. Grown around the coast, Gaepal, and salt fields, it is also called a `` Tung-sword '' and was designated as a natural monument in 1921. The seaweed grows on land and is enriched with various minerals and enzymes contained in the seawater. Especially, 100 g of seaweed contains 671 mg of calcium, 661 mg of magnesium, 475 mg of potassium, 441 mg of iron, 139 mg of phosphorus, 65.8 mg of iodine and sodium. Ingredients such as 6.5% and 15.7% of salt are known, and 5,200 mg of vegetable fiber and enzymes that degrade stool are contained. Pharmacological action is effective in nephritis, hepatitis and hypertension, hypotension, anemia, and improve the function of the thyroid gland.
이에, 본 발명자들은 종래의 치료제들의 부작용 등의 문제점을 극복하고자 천연물에서 혈당강하 효과가 있는 물질을 검색하던 중 포도씨 추출물 및 함초 추출물에서 혈당강하 및 체중 증가를 억제하는 효과가 있는 것을 확인하여 본 발명을 완성하였다.Thus, the inventors of the present invention to confirm that the effect of inhibiting the hypoglycemic and weight gain in the grape seed extract and seaweed extract while searching for a substance having a hypoglycemic effect in natural products to overcome the problems such as side effects of the conventional therapeutics Was completed.
따라서, 본 발명의 목적은 포도씨 및 함초의 추출혼합물을 주성분으로 포함하는 혈당강하 및 비만의 치료 및 예방용 조성물을 제공하는 것이다. Accordingly, it is an object of the present invention to provide a composition for the treatment and prevention of hypoglycemia and obesity comprising the extract mixture of grape seed and perilla as a main component.
상기 목적을 달성하기 위하여 본 발명은 포도씨 및 함초(Salicornia herbacea)의 추출혼합물을 주성분으로 포함하는 혈당강하 및 비만의 치료 및 예방용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for the treatment and prevention of hypoglycemia and obesity, including the extract mixture of grape seed and Salicornia herbacea as a main component.
상기 포도씨 및 함초의 추출혼합물은 포도씨 추출물 및 함초 추출물의 혼합비가 1:1인 것을 특징으로 한다.The extract mixture of grape seed and seaweed is characterized in that the mixing ratio of the grape seed extract and the seaweed extract is 1: 1.
상기 포도씨 추출물 및 함초 추출물은 물, 에탄올, 메탄올 등과 같은 극성용매 또는 이들의 혼합용매에 가용한 추출물, 바람직하게는 물 또는 에탄올에 가용한 추출물을 의미한다.The grape seed extract and the seaweed extract means an extract available in a polar solvent such as water, ethanol, methanol, or a mixed solvent thereof, preferably an extract available in water or ethanol.
이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 포도씨 및 함초의 추출혼합물 중 포도씨 추출물 및 함초 추출물은 각각 하기와 같은 방법으로 수득될 수 있다. 먼저, 포도씨 및 함초를 각각 채집하여 건조하고 마쇄기로 분말화한 후, 포도씨 및 함초 각각의 건조시료 중량의 약 2 내지 40배, 바람직하게는 약 3 내지 10배에 달하는 부피의 물 및 메탄올, 에탄올, 부탄올 등과 같은 C1 내지 C5의 저급알콜 또는 이들의 약 1:0.1 내지 1:10의 혼합비를 갖는 혼합용매로, 바람직하게는 물 또는 70 % 에탄올로 40 내지 100 ℃,바람직하게는 50 ℃에서 약 30 분 내지 24시간, 바람직하게는 1 내지 3시간동안 침지, 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출 등의 추출방법을 사용하여 추출한 다음, 진공여과에 의해 상층액을 회수하는 상기의 과정을 2 내지 5회, 바람직하게는 3회 반복 수행하여 상층액을 모으고 감압농축한 후 24 내지 72 시간, 바람직하게는 48시간 동안 증발 또는 동결건조하여 분말상태로 물, 저급 알콜 또는 이들의 혼합용매에 가용한 포도씨 추출물 및 함초 추출물을 각각 수득할 수 있다.Grape seed extract and seaweed extract in the extract mixture of grape seed and seaweed of the present invention can be obtained by the following method, respectively. First, grape seeds and seaweeds are collected, dried, and pulverized with a crusher, and then a volume of water, methanol, and ethanol of about 2 to 40 times, preferably about 3 to 10 times, the weight of each dry sample of grape seeds and seaweeds. C 1 to C 5 lower alcohols such as butanol or the like, or a mixed solvent having a mixing ratio of about 1: 0.1 to 1:10, preferably 40 to 100 ° C. with water or 70% ethanol, preferably 50 ° C. Extraction using extraction methods such as soaking, hydrothermal extraction, cold needle extraction, reflux cooling extraction or ultrasonic extraction for about 30 minutes to 24 hours, preferably 1 to 3 hours, and then recovering the supernatant by vacuum filtration. Repeat the procedure of 2 to 5 times, preferably 3 times to collect the supernatant, and concentrated under reduced pressure, and then evaporated or lyophilized for 24 to 72 hours, preferably 48 hours, in powder, water, lower alcohol or In a mixed solvent thereof can be obtained respectively the grape seed extract and extract of Salicornia available.
이 때, 상기 추출용매로 사용하는 에탄올은 100 % 에탄올을 사용하거나 90 내지 50 % 에탄올을 사용할 수 있으며, 또한, 추출용매는 상기 기술한 용매들에 한정되지 않고 공지의 모든 용매를 사용할 수 있다.In this case, the ethanol used as the extraction solvent may be 100% ethanol or 90 to 50% ethanol, and the extraction solvent is not limited to the solvents described above, and all known solvents may be used.
본 발명의 혼합물은 상기 방법으로 수득한 포도씨 추출물 및 함초 추출물을 혼합, 바람직하게는 1:1로 혼합하여 제조할 수 있다.The mixture of the present invention can be prepared by mixing, preferably 1: 1, the grape seed extract and the seaweed extract obtained by the above method.
본 발명은 상기 제법으로 제조된 포도씨 및 함초 추출혼합물, 바람직하게는 이들의 혼합비가 1:1인 혼합물을 주성분으로 포함하는 혈당강하 및 비만의 치료 및 예방용 약학조성물을 제공한다.The present invention provides a pharmaceutical composition for the treatment and prevention of hypoglycemia and obesity, comprising the grape seed and vinegar extract mixture prepared by the above method, preferably a mixture whose ratio is 1: 1.
본 발명의 상기 혼합물의 혈당강하 및 체중 증가 저해 효과는 ob 마우스를 대상으로 동물실험을 수행한 결과, 그 효과를 확인하였다.The hypoglycemic and weight gain inhibitory effects of the mixture of the present invention was confirmed by the results of animal experiments in ob mice.
본 발명의 상기 포도씨 및 함초 추출혼합물을 주성분으로 포함하는 혈당강하 및 비만의 치료 및 예방용 약학조성물은 조성물 총 중량에 대하여 상기 추출혼합물을 0.001 내지 50 중량%로 포함한다.The pharmaceutical composition for the treatment and prevention of hypoglycemia and obesity, which comprises the grape seed and seaweed extract mixture of the present invention as a main component, comprises 0.001 to 50% by weight of the extract mixture, based on the total weight of the composition.
이 때, 상기 추출혼합물의 함량이 0.001 중량% 미만인 경우 효과적인 효능을 위해선 다량의 투여가 필요할 수 있으며, 50 중량% 초과하는 경우 사용량이 많음에도 불구하고 효능이 저용량과 비슷할 수 있어 비경제적일 수 있다. 가장 바람직하기로는 혈당강하, 당뇨병 개선 및 비만 예방의 사용방법 및 사용목적에 따라 함량을 적절히 조절하는 것이 좋다.In this case, when the content of the extract mixture is less than 0.001% by weight, a large amount of administration may be necessary for effective efficacy, and when the amount exceeds 50% by weight, the efficacy may be similar to a low dose, which may be uneconomical. . Most preferably, the content is appropriately adjusted according to the method of use and purpose of lowering blood sugar, improving diabetes and preventing obesity.
또한, 본 발명의 상기 약학조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.In addition, the pharmaceutical composition of the present invention may further include suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
본 발명의 추출혼합물의 약학적 투여 형태는 이들의 약학적 허용 가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다. The pharmaceutical dosage forms of the extract mixtures of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable collection.
본 발명에 따른 포도씨 및 함초 추출혼합물을 주성분으로 포함하는 약학조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 또한, 추출혼합물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출혼합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Pharmaceutical compositions comprising the grape seed and perilla extract mixture according to the present invention as a main component, respectively, oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and the like according to conventional methods It can be formulated and used in the form of sterile injectable solutions. In addition, carriers, excipients and diluents that may be included in the composition comprising the extract mixture include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate , Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose ( It is prepared by mixing sucrose or lactose and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 추출혼합물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 추출혼합물은 1일 0.0001 내지 100 mg/kg으로, 바람직하게는 0.001 내지 100 mg/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위을 한정하는 것은 아니다.Preferred dosages of the extract mixtures of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the extract mixture of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably at 0.001 to 100 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
본 발명의 추출혼합물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 (intracerebroventricular) 주사에 의해 투여될 수 있다. The extract mixture of the present invention can be administered to mammals such as rats, mice, livestock, humans, and the like by various routes. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
또한, 본 발명은 혈당강하 또는 비만의 예방 및 개선 효과를 나타내는 상기 포도씨 및 함초 추출혼합물 및 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 건강기능식품을 제공한다. 상기 추출혼합물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다.In another aspect, the present invention provides a health functional food comprising the grape seed and seaweed extract mixture and food acceptable food additives exhibiting a blood sugar lowering or obesity prevention and improvement effect. Examples of the food to which the extract mixture can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.
또한, 혈당강하 및 비만의 예방 및 개선 효과를 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 추출혼합물의 양은 전체 식품 중량의 0.01 내지 15 중량 %로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1g의 비율로 가할 수 있다. It may also be added to foods or beverages for the purpose of preventing and improving blood sugar lowering and obesity. At this time, the amount of the extract mixture in the food or beverage may be added to 0.01 to 15% by weight of the total food weight, the health beverage composition is added in a ratio of 0.02 to 5 g, preferably 0.3 to 1g based on 100 ml Can be.
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출혼합물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The health functional beverage composition of the present invention is not particularly limited to other ingredients except for containing the extract mixture as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. . Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 추출혼합물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 추출혼합물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 추출혼합물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the extract mixture of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. In addition, the extract mixture of the present invention may contain a fruit flesh for the production of natural fruit juice and fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract mixture of the present invention.
이하, 본 발명을 하기 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by the following Examples and Experimental Examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실험예에 의해 한정되는 것은 아니다.However, the following Examples and Experimental Examples are only illustrative of the present invention, and the content of the present invention is not limited by the following Experimental Examples.
실시예 1. 포도씨 추출물 및 함초 추출물의 제조Example 1 Preparation of Grape Seed Extract and Seaweed Extract
포도씨 및 함초를 각각 채집하고 건조하여 건조상태의 포도씨 100 g 및 함초 100 g을 마쇄기로 곱게 마쇄한 후 여기에 70 % 에탄올 600 ㎖를 가하여 50 ℃에서 2시간 동안 침지한 후 여과하여 각각의 추출물을 수득한 다음 추출물은 진공회전증발기를 이용하여 에탄올을 완전히 제거하고 농축한 후, 동결건조기를 이용하여 48시간동안 수분을 완전히 제거하여 건조분말상태의 포도씨 추출물(9.8 g) 및 함초 추출물(9.8 g)을 각각 수득하였다.Grape seed and seaweed were collected and dried, and the dried grape seed and 100 g of finewort were ground finely with a crusher. Then, 600 ml of 70% ethanol was added thereto, soaked at 50 ° C. for 2 hours, and then filtered. The obtained extract was concentrated using a vacuum rotary evaporator to completely remove ethanol and concentrated, and then completely removed water using a lyophilizer for 48 hours to extract grape powder (9.8 g) and perilla extract (9.8 g) in a dry powder state. Were obtained respectively.
실시예 2. 포도씨 및 함초 추출혼합물의 제조Example 2. Preparation of Grape Seed and Seaweed Extract Mixture
상기 실시예 1에서 수득한 각각의 포도씨 추출물 및 함초 추출물을 1: 1로 혼합하여 포도씨 및 함초 추출혼합물을 제조한 후, 추출혼합물의 1/10을 10 ㎖의 물에 녹인 것을 원액(98 ㎎ 추출혼합물/㎖ 물)으로 하여 실험에 사용하였다. After mixing the grape seed extract and the seaweed extract obtained in Example 1 to 1: 1 to prepare a grape seed and the extract mixture, 1/10 of the extract mixture was dissolved in 10 ml of water stock extract (98 mg) Mixture / ml water).
실험예 1. 추출혼합물의 ob 마우스에서 혈당강하 효과Experimental Example 1. Hypoglycemic effect in ob mice of extract mixture
1-1. 실험동물의 사육 및 투여방법1-1. Breeding and Administration of Laboratory Animals
본 동물실험에서 사용한 실험동물은 C57BL/6J-Lepob (ob mouse)로 비만형 당뇨연구실험에 사용되는 동물로써 미국 JAX (The Jackson Laboratory)에서 구입하였다. 실험동물의 사육은 SPF 베리어 시스템(SPF barrier system)에서 행하여졌으며, 3-4주령이 되면 비만을 나타내는 동물을 선별하여 사용하였고, 실험동물의 연령은 9주령의 수컷을 이용하였다. 또한, 시험 직전에 체중과 혈당(basal blood glucose)을 측정하여 평균 수치가 각 군마다 비슷하게 조정하여 사용하였으며, 이때의 평균 혈당치는 270~280 mg/㎗ 내외로 하였다. 한편, 본 실험에 이용한 음성 대조군(아무런 물질도 투여하지 않음), 양성 대조군(DMSO용매 투여), 포도씨 및 함초 추출혼합물(50 mg), 포도씨 및 함초 추출혼합물(100 mg)을 3주간 실험동물에 투여하여 실험하였다.The experimental animal used in this animal experiment was C57BL / 6J-Lep ob (ob mouse), which was used in the obesity type diabetes research experiment and was purchased from JAX (The Jackson Laboratory) in the United States. The breeding of experimental animals was carried out in the SPF barrier system, and when the animals were 3-4 weeks old, the animals showing obesity were selected, and the age of the experimental animals was 9 weeks old male. In addition, immediately before the test body weight and blood glucose (basal blood glucose) was measured and the average value was similarly adjusted for each group, and the average blood sugar level was about 270 ~ 280 mg / ㎗. On the other hand, the negative control (no substance was administered), positive control (DMSO solvent administration), grape seed and seaweed extract mixture (50 mg), grape seed and seaweed extract mixture (100 mg) used in this experiment for 3 weeks in the experimental animals Dosing was tested.
1-2. 혈당강하 효과 실험1-2. Hypoglycemic effect test
상기 실시예 2에서 제조한 포도씨 및 함초 추출혼합물의 혈당강하 효과를 실험하기 위하여, 매일 오전 10시에 동물의 꼬리를 조금 잘라 혈액을 얻은 다음 자동혈당계(슈퍼 글루코카드2, Arkray Factory Inc., Japan)를 이용하여 혈당을 측정하였다. 이 후 상기 실시예 2의 추출혼합물을 식도용 바늘을 이용하여 경구투여(용량은 각각 체중 kg 당 50 mg, 100 mg이 되도록 투여)하였다. 이와 같은 혈당 측정을 3주간 매일 10시에 하였다. In order to test the hypoglycemic effect of the grape seed and vinegar extract mixture prepared in Example 2, the animal's tail was cut a little at 10 am every day to obtain blood, and then the blood glucose meter (Super Glucocard 2, Arkray Factory Inc., Japan). ), Blood glucose was measured. Thereafter, the extract mixture of Example 2 was administered orally using an esophageal needle (the doses were administered to 50 mg and 100 mg per kg of body weight, respectively). This blood glucose measurement was made every day at 10 o'clock for three weeks.
그 결과는 도 1에 나타내었으며, 도 1에서 보면 아무런 물질도 투여하지 않은 음성대조군은 250-285 mg/㎗의 혈당을 지속적으로 보였으며, 모두 95 %의 신뢰구간에서 움직이는 것을 확인할 수 있었다. 한편 DMSO 용매만을 투여한 양성대조군에서는 225-267 mg/㎗의 혈당을 보이는 것을 확인 할 수 있었다. 한편 상기 실시예 2의 추출혼합물을 50 mg/kg을 투여한 군에서는 134-188 mg/㎗의 혈당을 보여 대조군에 비해 효과가 현저하게 좋은 것을 확인할 수 있었다. 상기 추출혼합물을 100 mg/kg을 투여한 경우에는 112-167 mg/㎗의 혈당을 보여 50 mg/kg을 투여한 경우보다 약간 효과가 좋은 것을 확인할 수 있었다. 또한, 혈당의 강하는 추출혼합물을 투여하기 시작한 직후부터 나타나는 것이 아니라 저농도에서는 9일 후부터 나타나기 시작하였으며, 고농도에서는 6일 후부터 나타나는 것을 확인할 수 있었다.The results are shown in FIG. 1, and in FIG. 1, the negative control group, which was not administered any substance, continuously showed blood glucose of 250-285 mg / dL, and all of them were confirmed to move in the 95% confidence interval. On the other hand, the positive control group administered with only DMSO solvent showed a blood sugar of 225-267 mg / dl. On the other hand, in the group administered 50 mg / kg of the extract mixture of Example 2 showed a blood sugar of 134-188 mg / ㎗ was confirmed that the effect is significantly better than the control group. When the extract mixture was administered 100 mg / kg showed a blood sugar of 112-167 mg / ㎗ it was confirmed that the effect is slightly better than when administered 50 mg / kg. In addition, the drop in blood glucose did not appear immediately after the start of the administration of the extract mixture, but began to appear after 9 days at low concentrations, it was confirmed that after 6 days at high concentrations.
실험예 2. 추출혼합물의 ob 마우스에서 체중증가 억제 Experimental Example 2. Inhibition of weight gain in ob mice of extract mixture
상기 실시예 2의 포도씨 및 함초 추출혼합물의 체중증가 억제 효과를 알아보기 위하여 하기와 같은 실험을 수행하였다. 이때 실험동물의 사육 및 투여방법은 상기 실험예 1-1과 같으며, 실험은 매일 오전 10시에 동물의 체중을 측정하였다. 이 후 추출혼합물은 식도용 바늘을 이용하여 경구투여(용량은 각각 체중 kg 당 50 mg, 100 mg이 되도록 투여)하였다. 이와 같은 체중 측정을 3주간 매일 10시에 하였다. In order to determine the effect of inhibiting the increase in weight of the grape seed and vinegar extract mixture of Example 2 was carried out the following experiment. At this time, the breeding and administration of the experimental animals is the same as in Experimental Example 1-1, the experiment was measured the weight of the animal at 10 am daily. Thereafter, the extract mixture was administered orally using an esophageal needle (dose was administered to 50 mg and 100 mg per kg of body weight, respectively). This weight measurement was taken at 10 o'clock every day for three weeks.
그 결과는 도 2에 나타내었으며, 도 2에서 보면, 아무런 물질도 투여하지 않은 음성대조군과 DMSO 용매만을 투여한 양성대조군에 비해 상기 실시예 2의 추출혼합물을 투여한 군은 체중이 적게 증가하는 것을 확인할 수 있었으며, 특히 포도씨 및 함초 추출혼합물을 투여한 고용량인 100 mg/kg 보다는 오히려 50 mg/kg에서 더 좋은 효과를 확인할 수 있었다. The results are shown in FIG. 2, and in FIG. 2, the group administered with the extract mixture of Example 2 gained less weight than the negative control group administered with no substance and the positive control group administered with only DMSO solvent. In particular, it was confirmed that a better effect at 50 mg / kg rather than the high dose of 100 mg / kg administered especially grape seed and seaweed extract mixture.
실험예 3. 급성독성 실험Experimental Example 3. Acute Toxicity Test
3-1. 경구투여3-1. Oral administration
ICR계 마우스와 스프라그 도올리 랫트를 각각 10마리씩 4군으로 나누어 본 발명의 상기 실시예 2의 포도씨 및 함초 추출혼합물을 각각 100, 250, 500 및 1000 ㎎/㎏의 용량으로 경구 투여한 후 2주간 독성여부를 관찰한 결과 4군 모두에서 사망한 예가 한 마리도 없었고 외견상 대조군과 별다른 증상을 찾아볼 수 없었다. ICR-based mice and Sprague dooli rats were divided into four groups of 10 rats each, and the grape seed and seaweed extract mixtures of Example 2 of the present invention were orally administered at doses of 100, 250, 500 and 1000 mg / kg, respectively. As a result of daytime toxicity, none of the four groups died and no symptoms were apparent from the control group.
3-2. 복강투여3-2. Intraperitoneal administration
ICR계 마우스(몸무게 25 ±5 g)와 스프라그 도올리 랫트를 각각 10마리씩 4군으로 나누어 본 발명의 상기 실시예 2의 추출혼합물을 각각 25, 50, 100 및 200 ㎎/㎏의 용량으로 복강투여한 후 24시간 동안 독성여부를 관찰한 결과 4군 모두에서 사망한 예가 한 마리도 없었고 외견상 대조군과 별다른 증상을 찾아볼 수 없었다. ICR-based mice (weight 25 ± 5 g) and Sprague Dooli rats were divided into four groups of 10 rats each, and the extract mixture of Example 2 of the present invention was intraperitoneally dosed at 25, 50, 100 and 200 mg / kg, respectively. After 24 hours of administration, no toxicities were observed in all four groups and no symptoms were apparent in the control group.
실험 결과, 본 발명의 포도씨 및 함초 추출혼합물은 급성독성이 거의 없음이 확인되었다. As a result, it was confirmed that the grape seed and seaweed extract mixtures of the present invention have little acute toxicity.
하기에 본 발명의 추출혼합물을 포함하는 약학조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, an example of the preparation of a pharmaceutical composition including the extract mixture of the present invention will be described, but the present invention is not intended to be limited thereto but merely to describe in detail.
제제예 1. 산제의 제조Formulation Example 1 Preparation of Powder
상기 실시예 2의 추출혼합물 20 mg20 mg of the extract mixture of Example 2
유당 100 mgLactose 100 mg
탈크 10 mgTalc 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
제제예 2. 정제의 제조Formulation Example 2 Preparation of Tablet
상기 실시예 2의 추출혼합물 10 mg10 mg of the extract mixture of Example 2
옥수수전분 100 mgCorn starch 100 mg
유당 100 mgLactose 100 mg
스테아린산 마그네슘 2 mg2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.
제제예 3. 캅셀제의 제조 Formulation Example 3 Preparation of Capsule
상기 실시예 2의 추출혼합물 10 mg10 mg of the extract mixture of Example 2
결정성 셀룰로오스 3 mg3 mg of crystalline cellulose
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium Stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
제제예 4. 주사제의 제조Formulation Example 4 Preparation of Injection
상기 실시예 2의 추출혼합물 10 mg10 mg of the extract mixture of Example 2
만니톨 180 mgMannitol 180 mg
주사용 멸균 증류수 2974 mgSterile distilled water for injection 2974 mg
Na2HPO4,12H2O 26 mgNa 2 HPO 4, 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당(2 ㎖) 상기의 성분 함량으로 제조한다.According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).
제제예 5. 액제의 제조Formulation Example 5 Preparation of Liquid
상기 실시예 2의 추출혼합물 20 mg20 mg of the extract mixture of Example 2
이성화당 10 g10 g of isomerized sugar
만니톨 5 g5 g of mannitol
정제수 적량Purified water
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100 ㎖로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.According to the conventional method of preparing a liquid solution, each component is added to the purified water to dissolve it, the lemon flavor is added appropriately, the above components are mixed, purified water is added, the whole is adjusted to 100 ml by the addition of purified water, and then filled in a brown bottle. The solution is prepared by sterilization.
제제예 6. 건강 음료의 제조Formulation Example 6 Preparation of Healthy Drink
상기 실시예 2의 추출혼합물 100 ㎎100 mg of the extract mixture of Example 2
비타민 C 15 g15 g of vitamin C
비타민 E(분말) 100 g100 g of vitamin E (powder)
젖산철 19.75 gIron lactate 19.75 g
산화아연 3.5 g3.5 g of zinc oxide
니코틴산아미드 3.5 gNicotinamide 3.5 g
비타민 A 0.2 g0.2 g of vitamin A
비타민 B1 0.25 g0.25 g of vitamin B 1
비타민 B2 0.3 g0.3 g of vitamin B 2
물 정량Water quantification
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 ℓ용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. After mixing the above components in accordance with the conventional healthy beverage production method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilized and stored in the refrigerator and then Used to prepare the healthy beverage composition of the invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is mixed with a component suitable for a favorite beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
이상 살펴본 바와 같이, 본 발명의 포도씨 및 함초 추출혼합물을 주성분으로 포함하는 조성물은 당뇨 및 비만 마우스에서 혈당강하 및 체중증가 저하 효과가 탁월할 뿐 아니라 인체에 무해하므로 혈당강하 및 비만의 치료 및 예방용 조성물로써 의약품 및 건강기능식품에 사용할 수 있다. As described above, the composition comprising the grape seed and the herb extract mixture of the present invention as a main component is excellent in lowering blood sugar and lowering weight gain effect in diabetic and obese mice as well as harmless to the human body for the treatment and prevention of blood sugar lowering and obesity As a composition, it can be used in medicine and health food.
도 1은 포도씨 및 함초의 추출혼합물을 비만마우스인 ob 마우스에 3주간 투여하였을 때, 혈당강하 효과에 미치는 영향을 측정한 도이고, 1 is a diagram measuring the effect on the hypoglycemic effect when the extract mixture of grape seed and seaweed was administered to ob mice, obese mice for 3 weeks,
도 2는 포도씨 및 함초의 추출혼합물을 비만마우스인 ob 마우스에 3주간 투여하였을 때, 비만 억제 효과에 미치는 영향을 측정하기 위해 체중을 측정한 것이다. Figure 2 is the body weight was measured to determine the effect on the obesity inhibitory effect when administered for three weeks to the obese mice obesity extract mixture of grape seed and seaweed.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020040002805A KR100610565B1 (en) | 2004-01-15 | 2004-01-15 | Composition comprising mixture of the extract of grape seed and Salicornia herbacea for lowering blood glucose and treating and preventing obesity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020040002805A KR100610565B1 (en) | 2004-01-15 | 2004-01-15 | Composition comprising mixture of the extract of grape seed and Salicornia herbacea for lowering blood glucose and treating and preventing obesity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20050075045A true KR20050075045A (en) | 2005-07-20 |
| KR100610565B1 KR100610565B1 (en) | 2006-08-08 |
Family
ID=37263389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020040002805A KR100610565B1 (en) | 2004-01-15 | 2004-01-15 | Composition comprising mixture of the extract of grape seed and Salicornia herbacea for lowering blood glucose and treating and preventing obesity |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100610565B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022078230A (en) * | 2017-05-24 | 2022-05-24 | 共栄化学工業株式会社 | Skin external preparations |
| KR20240065851A (en) | 2022-11-07 | 2024-05-14 | 건국대학교 산학협력단 | Composition for the prevention and treatment of obesity comprising extract of fermented salicornia herbacea l. and extract of fermented artemisia annua l. |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101139512B1 (en) * | 2009-04-29 | 2012-05-02 | 전라남도 | Method for preparing extracts containing antioxidants of glasswort |
-
2004
- 2004-01-15 KR KR1020040002805A patent/KR100610565B1/en active IP Right Grant
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022078230A (en) * | 2017-05-24 | 2022-05-24 | 共栄化学工業株式会社 | Skin external preparations |
| KR20240065851A (en) | 2022-11-07 | 2024-05-14 | 건국대학교 산학협력단 | Composition for the prevention and treatment of obesity comprising extract of fermented salicornia herbacea l. and extract of fermented artemisia annua l. |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100610565B1 (en) | 2006-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100610565B1 (en) | Composition comprising mixture of the extract of grape seed and Salicornia herbacea for lowering blood glucose and treating and preventing obesity | |
| KR100527109B1 (en) | Pharmaceutical composition comprising the extract of Allium tuberosum ROTTER for the prevention and treatment of gout. | |
| KR102292059B1 (en) | Composition comprising of the extract of Cissus verticillata and Cyclopia Intermedia as an active ingredient for preventing or treating diabetic complication and diabetes | |
| KR100527105B1 (en) | Pharmaceutical composition comprising the extract of Allium tuberosum ROTTER for the prevention and treatment of gout | |
| KR100543405B1 (en) | Composition comprising the extract of Allium victorialis L. var. platyphyllum for treating or preventing diabetes mellitus | |
| KR20070097868A (en) | Composition comprising an allium cepa l. skin extract for preventing and treating diabetes mellitus | |
| KR100939089B1 (en) | Pharmaceutical composition comprising shikonin derivatives from Lithospermum erythrorhizon for treating or preventing diabetes mellitus. | |
| KR101001159B1 (en) | Composition for preventing or improving the diabete containing eriobotrya japonica extract | |
| KR101134781B1 (en) | Composition comprising an the extract of Allium fistulosum L. for preventing and treating diabetes mellitus | |
| KR102003354B1 (en) | Composition comprising Spike mulberry mistletoe extract for treating diabetes | |
| KR20050003665A (en) | Composition comprising an extract of Peucedanum japonicum for preventing and treating diabetes | |
| KR100551464B1 (en) | Composition comprising an extract of Saururus chinensis BAILL. for preventing and treating diabetes mellitus | |
| KR100468073B1 (en) | Composition comprising from an extract of Salicornia herbacea or isorhamnetin-3-O-β-D-glucoside isolated therefrom | |
| KR102302047B1 (en) | Composition for hepatoprotective and ameliorating hangover | |
| KR102292060B1 (en) | Composition comprising of the combined extract of Cissus verticillata and Cyclopia Intermedia as an active ingredient for preventing or treating obesity | |
| KR20060025914A (en) | Composition comprising the complex crude extract ??bae dang su ??for preventing and treating diabetes mellitus | |
| KR102493496B1 (en) | Composition for alleviating and improving liver damage derived from natural products | |
| KR20120033443A (en) | Antifatigue composition comprising the extracts, fractions or isolated compounds of eisenia bicyclis and process for preparation thereof | |
| KR100547558B1 (en) | Composition for the prevention and treatment of hepatitis containing acid garlic extract as an active ingredient | |
| KR20050080810A (en) | Composition comprising the extract of acanthopanax senticosus for preventing and treating diabetes | |
| KR100605286B1 (en) | Composition comprising an extract of Trapa japonica Flerov. for preventing and treating diabetes mellitus | |
| KR20220142073A (en) | Composition for regulating blood glucose comprising Cudrania tricuspidata leaf and white grub as an effective ingredient | |
| KR101219736B1 (en) | Composotion for facilitate secretion of testosterone comprising silk worm dry powder and its use | |
| KR100712195B1 (en) | Composition comprising chaga mushroom extract having neuronal cell-protecting activity for preventing and treating brain disease | |
| KR20060129610A (en) | Composition comprising bamboo extract for treating or preventing diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| N231 | Notification of change of applicant | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20130802 Year of fee payment: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20140523 Year of fee payment: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20170725 Year of fee payment: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20190528 Year of fee payment: 14 |